aBLA Filing Intelligence & Biosimilar Opportunity

Elrexfio

Elranatamab-Bcmm

Anticancer

Subcutaneous Injection

Elrexfio is a weekly subcutaneous injection for adults with relapsed or refractory multiple myeloma who have tried at least four prior treatments. It’s a bispecific antibody that directs T cells to attack myeloma cells by targeting BCMA and CD3.

Approval Date

14-Aug-23

Data Exclusivity Expiry

14-Aug-27

Market Exclusivity Expiry

14-Aug-35

Commercial snapshot

Market performance & projections

Revenue ($M)

304

CAGR (%)

0.3379

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

425

2027

578

2028

800

2029

974

2030

1122

2031

1266

2032

1406

Molecule profile

Details & specifications

Molecule

Elranatamab-Bcmm

Innovator

PFIZER

Dosage Form

Subcutaneous Injection

Strength

44 mg/1.1 mL and 76 mg/1.9 mL

Therapeutic Category

Anticancer

Usage

To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.